Dok Hyun Yoon
Overview
Explore the profile of Dok Hyun Yoon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
251
Citations
2768
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee J, Oh S, Lee T, Lee S, Kim N, Pak M, et al.
Br J Haematol
. 2025 Mar;
PMID: 40065083
No abstract available.
2.
Lee J, Song S, Shin Y, Kim S, Yoo Y, Joo J, et al.
Leuk Lymphoma
. 2025 Mar;
:1-8.
PMID: 40048624
This study evaluated the efficacy and safety of 20.0 Gy versus 30.6 Gy radiotherapy for conjunctival MALT lymphoma in 76 lesions treated between 2010 and 2022. The 30.6 Gy group...
3.
Tan Y, Yoon D, Davies A, Buske C, Boo Y, Somasundaram N, et al.
Discov Oncol
. 2025 Feb;
16(1):181.
PMID: 39951161
Chimeric antigen receptor T-cell (CAR-T)-mediated therapies have shown promising clinical benefit in patients with refractory or relapsing (R/R) diffuse large B-cell lymphoma (DLBCL). However, CAR-T treatment presents challenges such as...
4.
Jung S, Koh Y, Kim M, Kim J, Moon J, Min C, et al.
Blood Res
. 2025 Feb;
60(1):9.
PMID: 39903326
Multiple myeloma (MM), a hematological malignancy, is characterized by malignant plasma cell proliferation in the bone marrow. Recent treatment advances have significantly improved patient outcomes associated with MM. In this...
5.
Abramson J, Ku M, Hertzberg M, Huang H, Fox C, Zhang H, et al.
Lancet
. 2024 Nov;
404(10466):1940-1954.
PMID: 39550172
Background: Glofitamab monotherapy induces durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma after two or more previous therapies, but has not previously been assessed as a...
6.
Zinzani P, Izutsu K, Mehta-Shah N, Barta S, Ishitsuka K, Cordoba R, et al.
Lancet Oncol
. 2024 Nov;
25(12):1602-1613.
PMID: 39486433
Background: Peripheral T-cell lymphomas are aggressive non-Hodgkin lymphomas with few treatment options for relapsed or refractory disease. Valemetostat tosylate (valemetostat) is a potent, novel, dual inhibitor of EZH2 and EZH1....
7.
Han M, Jeong S, Suh C, Park H, Guenette J, Huang R, et al.
Front Neurol
. 2024 Oct;
15:1392831.
PMID: 39474369
Objectives: We aim to assess the pooled incidence of immune effector cell-associated neurotoxicity syndrome (ICANS) in clinical trials and real-world studies of chimeric antigen receptor (CAR) T-cell therapy for hematologic...
8.
Yi J, Kim S, Kim S, Jung J, Yoon D
Cancer Res Treat
. 2024 Aug;
PMID: 39164085
Purpose: Given that 40~50% of primary central nervous system lymphoma (PCNSL) tissues exhibit aberrancy on 9p24.1, immune-checkpoint inhibitors (ICI) may work for the disease. Materials And Methods: To define the...
9.
Oh M, Cho H, Park J, Kim H, Go H, Park C, et al.
Neuro Oncol
. 2024 Aug;
26(12):2377-2387.
PMID: 39097777
Background: The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in the prognostication and response evaluation of primary central nervous system lymphoma (PCNSL) remains inadequately defined. Methods: We conducted a...
10.
Jang H, Bae S, Jung J, Cho H, Yoon D, Kim S
J Korean Med Sci
. 2024 Jul;
39(28):e224.
PMID: 39048304
The seropositivity of measles antibodies among 261 autologous stem cell transplant recipients (ASCTs) in Korea, assessed approximately 1-2 years after transplant (median, 11 months; interquartile range, 9-14), was significantly lower...